title: Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.
abstract: OBJECTIVE
  To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models.
  
  
  METHODS
  The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg(-1)·d(-1) and 100 mg·kg(-1)·d(-1)) groups and an Aricept (2 mg·kg(-1)·d(-1)) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris water-maze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot.
  
  
  RESULTS
  In Morris water-maze test, evodiamine (100 mg·kg(-1)·d(-1)) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg(-1)·d(-1)) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease.
  
  
  CONCLUSIONS
  The results indicate that evodiamine (100 mg·kg(-1)·d(-1)) improves cognitive abilities in the transgenic models of Alzheimer's disease.
authors.affiliation: Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing, China.
authors.forename: Shu-min
authors.initials: SM
authors.lastname: Yuan
authors.forename: Kai
authors.initials: K
authors.lastname: Gao
authors.forename: Dong-mei
authors.initials: DM
authors.lastname: Wang
authors.forename: Xiong-zhi
authors.initials: XZ
authors.lastname: Quan
authors.forename: Jiang-ning
authors.initials: JN
authors.lastname: Liu
authors.forename: Chun-mei
authors.initials: CM
authors.lastname: Ma
authors.forename: Chuan
authors.initials: C
authors.lastname: Qin
authors.forename: Lian-feng
authors.initials: LF
authors.lastname: Zhang
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D003071:Cognition / Q000187:drug effects*; D004195:Disease Models, Animal; D018782:Maze Learning; D008568:Memory / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D053764:Presenilin-1 / Q000235:genetics; D011799:Quinazolines / Q000008:administration & dosage* / Q000494:pharmacology*; D011897:Random Allocation
chemical_list: D016564:Amyloid beta-Protein Precursor; D053764:Presenilin-1; D011799:Quinazolines; C049639:evodiamine